Short Interest in ProPhase Labs Inc (NASDAQ:PRPH) Declines By 75.8%
ProPhase Labs Inc (NASDAQ:PRPH) saw a large decrease in short interest in the month of June. As of June 30th, there was short interest totalling 800 shares, a decrease of 75.8% from the May 30th total of 3,300 shares. Based on an average daily volume of 10,300 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s shares are sold short.
ProPhase Labs stock traded down $0.05 during midday trading on Friday, reaching $2.02. The stock had a trading volume of 5,535 shares, compared to its average volume of 15,897. ProPhase Labs has a 52-week low of $2.01 and a 52-week high of $4.00. The stock has a fifty day simple moving average of $2.68.
ProPhase Labs (NASDAQ:PRPH) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.09) earnings per share for the quarter. ProPhase Labs had a negative return on equity of 14.54% and a negative net margin of 23.26%. The firm had revenue of $2.32 million during the quarter.
An institutional investor recently bought a new position in ProPhase Labs stock. Dimensional Fund Advisors LP acquired a new position in ProPhase Labs Inc (NASDAQ:PRPH) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,817 shares of the company’s stock, valued at approximately $34,000. Dimensional Fund Advisors LP owned 0.09% of ProPhase Labs at the end of the most recent reporting period. 4.31% of the stock is owned by institutional investors and hedge funds.
ProPhase Labs Company Profile
ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.
Recommended Story: Earnings Per Share
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.